



#6.

## SEQUENCE LISTING

<110> GENZYME CORPORATION  
Scaria, Abraham  
Wadsworth, Samuel C.

<120> METHODS FOR TREATING BLOOD COAGULATION DISORDERS

<130> 5046US

<140> US 10/057,620  
<141> 2001-10-25

<150> PCT/US01/51391  
<151> 2001-10-25

<150> US 60/307,492  
<151> 2001-07-24

<150> US 60/243,046  
<151> 2000-10-25

<160> 20

<170> PatentIn version 3.2

<210> 1  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 1

Ser Lys Pro Gln Gly Arg Ile Val  
1 5

<210> 2  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 2

Ser Lys Arg Gln Lys Arg Ile Val  
1 5

<210> 3  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 3

Ser Lys Pro Gln Gly Arg Arg Arg Arg Ala Asn Ile Val  
1 5 10

<210> 4  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 4

Ser Lys Pro Gln Gly Arg Arg Arg Arg Ser Ile Val  
1 5 10

<210> 5  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 5

Ser Lys Arg Gln Lys Arg Ala Ile Val  
1 5

<210> 6  
<211> 11  
<212> PRT  
<213> Homo sapiens

<400> 6

Ser Lys Arg Gln Arg Arg Ala Asn Gly Gly Lys  
1 5 10

<210> 7  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 7

Arg Lys Arg Gln Lys Arg Ile Val  
1 5

<210> 8  
<211> 4  
<212> PRT  
<213> Homo sapiens

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> X = Any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> X = Any amino acid residue

<400> 8

Arg Xaa Xaa Arg  
1

<210> 9  
<211> 8  
<212> PRT  
<213> Homo sapiens

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X = Arg or Lys

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> X = Arg or Lys

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> X = Leu or Val or Phe

<400> 9

Xaa Lys Xaa Gln Xaa Arg Ile Val  
1 5

<210> 10  
<211> 4  
<212> PRT  
<213> Homo sapiens

<400> 10

Arg Gln Lys Arg  
1

<210> 11  
<211> 4  
<212> PRT  
<213> Homo sapiens

<400> 11

Pro Gln Gly Arg  
1

<210> 12  
<211> 39  
<212> DNA  
<213> Artificial

<220>  
<223> Oligonucleotide primer

<400> 12  
ctagcctagg ccaccatggg ctcccaggcc ctcaggctc

39

<210> 13  
<211> 34  
<212> DNA  
<213> Artificial

<220>  
<223> Oligonucleotide primer

<400> 13

ccttaattaa ctagggaaat ggggctcgca ggag

34

<210> 14  
<211> 21  
<212> DNA  
<213> Artificial

<220>  
<223> Oligonucleotide primer

<400> 14  
gctagcctat cggccttggg g

21

<210> 15  
<211> 36  
<212> DNA  
<213> Artificial

<220>  
<223> Oligonucleotide primer

<400> 15  
tgcaccggcg ccggcgcat tgggggggca aggtgt

36

<210> 16  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> Oligonucleotide primer

<400> 16  
agcaaacgcc aaaagcgaat tgtggggggc aag

33

<210> 17  
<211> 4  
<212> PRT  
<213> Homo sapiens

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> X = Any amino acid residue

<400> 17

Arg Xaa Lys Arg  
1

<210> 18  
<211> 4  
<212> PRT  
<213> Homo sapiens

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)

<223> X = Any amino acid residue

<400> 18

Arg Xaa Arg Arg

1

<210> 19

<211> 6

<212> PRT

<213> Homo sapiens

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X = Arg or Lys

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> X = Any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> X = Any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> X = Arg or Lys

<400> 19

Xaa Xaa Arg Xaa Xaa Arg

1

5

<210> 20

<211> 6

<212> PRT

<213> Homo sapiens

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X = Arg or Lys

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> X = Any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> X = Arg or Lys

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> X = Any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> X = Leu or Val or Phe  
  
<400> 20

Xaa Xaa Xaa Xaa Xaa Glx  
1 5